上海医药(02607)：二羟丙茶碱注射液通过仿制药一致性评价

Core Viewpoint - Shanghai Pharmaceuticals has received approval for its Dihydroxypropyl Theophylline Injection from the National Medical Products Administration, indicating successful completion of the consistency evaluation for generic drug quality and efficacy [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., is responsible for the Dihydroxypropyl Theophylline Injection [1] - The approval was granted through a supplementary application, with the notification number 2025B04012 [1] - The drug has passed the consistency evaluation for quality and efficacy as a generic medication [1]